Why More Capacity Isn’t Always the Answer for Growing CDMOs

Demand for pharmaceutical manufacturing capacity continues to grow. Sponsors are facing increasing market and supply pressures, new therapeutic modalities are creating more complex manufacturing requirements, and CDMOs are being asked to bring programs into production faster.

The natural response to growth is often to add capacity: more people, more equipment, more production lines, or even new facilities.

But what if capacity isn’t actually the constraint?

For many growing CDMOs, the bigger challenge is getting the most from the capacity they already have. Manual processes, disconnected systems, inefficient workflows, quality bottlenecks, and increasing operational complexity can all limit how much an existing manufacturing operation can support.

Before adding capacity, leading CDMOs are looking more closely at what’s actually constraining it.

Why CDMO Growth Is Creating a Different Kind of Capacity Challenge

Every New Sponsor Adds More Than Volume

Adding another sponsor today doesn’t necessarily mean producing more of the same thing.

A new program can introduce entirely different recipes, workflows, documentation, quality requirements, validation activities, and production timelines. As CDMOs expand into cell and gene therapies, RNA therapeutics, antibody-drug conjugates (ADCs), radiopharmaceuticals, and specialized fill-finish operations, that complexity continues to grow.

Sponsor Expectations Are Growing, Too

At the same time, sponsors are facing their own market and supply pressures. They expect CDMO partners to onboard programs quickly, provide greater manufacturing visibility, maintain quality and compliance, and respond as demand changes.

For multi-site CDMOs, another layer of complexity emerges: processes, data, technology, and quality practices must increasingly work across facilities.

The result is an important distinction:

Physical manufacturing capacity and usable manufacturing capacity aren’t always the same thing.

Where Does Manufacturing Capacity Actually Get Lost?

Available Space Doesn’t Always Mean Available Capacity

A facility can have available equipment and production space and still struggle to take on additional programs efficiently.

The constraint may be hiding elsewhere.

Technology transfer can take longer than necessary because every program is approached differently. Operators may spend significant time completing manual documentation. Quality teams can become overwhelmed reviewing batch records. Information may need to be reconciled across disconnected systems. Training requirements increase as products and processes multiply.

Small Inefficiencies Compound as You Grow

Individually, these inefficiencies may seem manageable. But as the number of sponsors, products, and sites increases, they compound.

Eventually, a CDMO can appear to have a capacity problem when what it actually has is an execution bottleneck.

Look at Three Assets Before Adding More Capacity

Before investing in additional capacity, CDMOs can ask a simpler question:

Are we getting everything we can from the people, systems, and equipment we already have?

1. People: Where Is Skilled Time Going?

Highly skilled manufacturing and quality professionals are difficult to replace – and their time is valuable.

How much of that time is spent manufacturing product, solving problems, and improving operations versus completing documentation, entering data, reconciling information, searching for records, or performing repetitive reviews?

Reducing administrative work doesn’t just improve productivity. It creates additional capacity within the existing workforce.

2. Systems: Are You Getting Full Value from Existing Technology?

Many pharmaceutical manufacturers already have significant technology investments in place, but that doesn’t mean they’re getting full value from them.

Disconnected systems, manual handoffs, underutilized functionality, and processes built around legacy ways of working can leave significant value locked inside the operation.

Before adding another system, leading organizations look at whether existing technology can be better integrated, standardized, or utilized to remove friction from manufacturing execution.

3. Equipment: Is Utilization Really the Constraint?

Equipment utilization is another area where the apparent constraint may not tell the whole story.

Is equipment genuinely running at its practical limit? Or are changeovers, scheduling, downtime, material availability, process variability, or manual workflows reducing how effectively that equipment can be used?

Better visibility into what happens on the manufacturing floor can help organizations distinguish a true equipment constraint from an operational one.

More Capacity Can Magnify a Broken Operating Model

Don’t Scale the Bottleneck

There are times when adding manufacturing capacity is absolutely necessary.

But adding capacity without addressing the underlying operating model can create a new problem: you scale the bottleneck along with the business.

A new production line still requires processes, people, training, quality oversight, data, and systems. A new facility introduces another operation that must be governed and coordinated. More sponsors mean more programs that need to be transferred, validated, executed, and reviewed.

If those processes are already creating friction, expansion can multiply the complexity.

Ask Whether the Operating Model Is Ready

That’s why capacity planning shouldn’t only ask how much additional manufacturing space or equipment an organization needs. It should also ask whether the operating model underneath that capacity is ready to scale.

What Leading CDMOs Are Doing Differently

Optimize Before You Expand

The CDMOs best positioned for growth aren’t waiting until they hit a capacity wall to rethink how manufacturing works.

They’re identifying operational bottlenecks before assuming physical capacity is the problem. They’re standardizing repeatable execution while preserving the flexibility individual sponsors require. They’re looking for opportunities to get more from existing people, systems, and equipment.

Use Digital Manufacturing to Unlock Capacity

Digital manufacturing also plays an increasingly important role.

Electronic execution can reduce manual documentation and data entry. Standardized workflows can make processes more repeatable. Integrated manufacturing data can give operations and quality teams greater visibility into what is happening on the floor. Capabilities such as electronic batch records and Review by Exception can help quality teams focus their attention where it’s needed rather than treating every record the same way.

The goal isn’t digitization for its own sake. It’s creating an operating environment capable of supporting more programs and more complexity without requiring resources to grow at the same rate.

When More Capacity Is the Answer

Expansion Still Matters

None of this means pharmaceutical manufacturers should stop investing in capacity.

New facilities, production lines, equipment, and people will remain essential as demand grows and new therapies reach commercial scale.

The difference is what sits underneath that investment.

Build the Foundation Before You Expand

When repeatable processes, standardized execution, strong quality systems, and scalable digital infrastructure are already in place, new capacity can be brought online without recreating the operating model every time.

In other words, the best time to solve an execution problem is before you turn it into a capacity problem.

Unlock Capacity Before You Add It

As CDMOs take on more sponsors, modalities, and manufacturing programs, capacity will remain an important part of the growth conversation.

But it shouldn’t always be the first question.

Before asking, “How much more capacity do we need?” it may be worth asking:

“What’s preventing us from getting more from the capacity we already have?”

For nearly four decades, POMS has worked exclusively with pharmaceutical manufacturers and CDMOs to improve manufacturing execution and build scalable digital foundations. Our purpose-built MES helps organizations standardize execution, improve manufacturing visibility, reduce manual processes, and prepare operations for future growth.

If you’re evaluating how your manufacturing operation can support its next stage of growth, contact POMS to start the conversation: sales@poms.com .